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Abstract – There is a number of photosynthetically produced small molecules that have previously been validated through SARS-
CoV spike protein interaction assays for selectivity and effectivity in our database. Our specialty database, the AVIRA-DB, has 
been built from scientific papers that published results regarding selective & effective CoV-2 spike protein binding inhibitors 
that prevent virus binding to the Angiotensin Converting Enzyme type 2 (ACE2). These data have been accumulated since 2003, 
the time of the first well documented coronavirus pandemic. To develop our anti-viral nutraceutical capsule we favoured small 
molecules (Mw <1000 Dalton) from edible plant parts that are enriched in experimentally evaluated coronavirus inhibitors. From 
this “AVIRA-DB” we screened for local culture varieties of vegetables and spices that are enriched in the anti-viral hits. Thus, 
AVIRA is the first knowledge-based nutraceutical composition that was validated by selective anti-CoV-2’s spike protein assays, 
performed in silico, -vitro & -vivo. From Chemo- & Bio-text-mined meta-data from literature and patents resulted in druggable 
flavonoids and flavonols, which were validated as anti-CoV-2 spike protein directed small molecules that are preventing the 
binding of the virus to ACE2. 
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INTRODUCTION 
 
In silico chemo-, bio-informatics search for network medicine  
 
Severe acute respiratory syndrome coronavirus (SARS-CoV) 
is the pathogen of SARS, which caused the 1st global panic 
in 2003 (Poutanen et al., 2003; Tsang et al., 2003). Since this 
coronavirus pandemics, it is well established that the 
Angiotensin Converting Enzyme type 2 (ACE2) is primarily 
used for docking and cellular entry of (+) RNA of SARS-
CoV. Furthermore, the spike protein is highly mutable upon 
jumping from one species to another, including humans (Fig. 
1). Systematic literature and patent searches were performed 
by molecular virologists and biologists in our laboratory for 
a better understanding of the quantitative Structure Activity 
Relationships (qSAR) of druggable leads that are capable of 
destroying interactions of cellular receptor with the spike 
protein of SARS CoV-2 virus (Chen, Han, Wang, & Zhao, 
2020; Messina et al., 2020). Annotation of data of interests 
Figure 1. Structural and mechanistic interaction of CoV-2 
with the ACE2 virus receptor (Jiang et. al 2020). Source: 
https://doi.org/10.1016/j.it.2020.03.007  
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was carried out with systematic and extensive manual text 
mining before upload in the “AVIRA-DB”. Up till know 
(2020Q3) more than 1500 texts and tables were checked from 
patents and peer reviewed journal articles to prepare this 
overview and the 1st evidence based food supplement, called 
AVIRA. 
 
MATERIALS AND METHODS 
 
Screening by key words and collection of publications for 
uploading data into the AVIRA-DB  
  
Figure 2. BioDjinnTM Knowledge Management System 
 
The BioDjinnTM proprietary knowledge management and 
taxonomy system of the Acheuron Ltd (Fig.2) was utilized to 
upload the AVIRA-DB by curators familiar with the best 
practices of molecular biology and virology. The PubMed 
(NLM) has been recently rescreened, to find relevant 
publications concerning the current coronavirus pandemic, 
i.e. ACE2 (Nicolau, Noleto, & Medeiros, 2020), spike protein 
inhibitor (Sinha et al., 2020; Xia et al., 2020), COVID 
flavonoid (Das, Majumder, Mandal, & Basak, 2020; Ngwa et 
al., 2020), spike protein assay (Chan et al., 2009; Gniffke et 
al., 2020; He et al., 2005; Jaimes, Millet, Goldstein, 
Whittaker, & Straus, 2019; Manopo et al., 2005; Woo et al., 
2005; Yan et al., 2007; Zhao et al., 2005) (Table 1.).  
 
Table 1. Number of publications for keywords 
Keyword Year of 
publication 
Number of 
publications 
   
COVID-19 2003-2020 44916 
CoV-2 2003-2020 8010 
ACE2 2003-2020 1066 
spike protein binding 2003-2020 98 
spike protein inhibitor 2020 2 
anti-viral 2003-2020 1078 
COVID flavonoid 2020 2 
Cov-2 inhibitor 2003-2020 53 
Spike protein assay 2005-2020 8 
 
To find plant parts that concentrate either in vitro and -vivo 
spike protein inhibitor assay (i.e. Cov-2 spike protein 
pseudotyped) (Chan et al., 2009) or clinically tried non-toxic 
druggable substances the curators also used the proprietary 
BioDjinnTM software to upload the AVIRA-DB with 
previously determined enrichments of bioactive anti-virals’ 
data. 
 
Typical HT-screening essays for antiviral small molecular 
leads 
Typically, Frontal Affinity Chromatography-Mass 
Spectrometry (FAC/MS) is employed to screen small 
molecule libraries from herbs, including Prunella vulgaris 
and Saussurea lappa Clarks that exhibited antiviral activities, 
i.e. against HIV-1 (Busschots, De Rijck, Christ, & Debyser, 
2009; Chang & Yeung, 1988; Yi et al., 2004; Zeng et al., 
2005). 
 
Pseudotyped virus infection assay is preferred to search for 
drugs that can interfere with the entry of SARS-CoV into host 
cells 
Briefly, inhibitory activities of SARS patients’ sera and 
selected small molecules against the HIV-luc/SARS 
pseudotyped virus to enter Vero E6 cells are evaluated by 
determination of inhibitory activities of sera of SARS-CoV 
patients. The ability of the SARS patient sera to block the 
infectivity of HIV-luc/SARS (SARS) vs the absence of such 
blocking activity in normal serum was noted. Also, the lack 
of neutralizing activity of the SARS sera against the 
pseudotyped virus bearing the G protein of Vesicular 
Stomatitis Virus could infect the target cells at a similar level 
to that of HIV-luc/SARS.  
 
Nutraceuticals enriched with AVIRA-DB guided anti-viral 
agents 
 
Figure 3. Overall protein folds of human SARS-CoV core 
RBD (receptor-binding domain, cyan), and RBM (receptor-
binding motif, magenta) in complex with human ACE2 
(green) (Source: Wan, Shang, Graham, Baric, & Li, 2020). 
 
The AVIRA herbal food supplement was designed by curators 
of Acheuron Ltd. employing the BioDjinnTM database 
platform to upload the AVIRA-DB and evaluate small 
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molecule ingredients anti- CoV-2 spike protein directed 
druggable inhibitors. The virologist curators looked at 
identified number of small molecules that bind avidly to the 
SARS CoV-S2 protein and can interfere with the entry of 
SARS-CoV into Vero E6 cells, with potent antiviral activities 
against wild-type SARS-CoV with EC50 values, typically, of 
the low micro-molar range (Messina et al., 2020). 
 
Grinded plant parts (>300 mm) enriched with experimentally 
tried BIOFLAVONOIDS that are tried in number of evident-
based protocols, selectively bind to the spike protein of CoV-
2 and prevent binding of the Human SARS-CoV S1’s 
RBD/RBM to ACE2, the cellular receptor counterpart (Fig. 3 
& Table 2). 
 
 
 
Figure 4. Alignment of the receptor binding motif (RBM) of SARS-S with corresponding sequences of bat-associated 
betacoronavirus S1 proteins, which reveals that SARS-CoV-2 possesses crucial amino acid residues for ACE2 binding 
(Hoffmann et al., 2020). 
 
 
Figure 5. Homologous Macro Domains in SARS-CoV-2 and rubella virus determined by structure-guided sequence alignment 
using the crystal structure of the SARS-CoV-2 Macro domain bound to ADP ribose as the template (Protein Data Bank entry 
6W02) Source: Young et al. 2020 https://doi.org/10.1101/2020.04.10.20053207 
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Preparation of the AVIRA food supplement 
The AVIRA-DB has been searched for natural enrichments 
of small molecules with promising (i.e. Kd in micromolar 
range) spike protein binding and/or inhibitor substances 
enrichments in edible plants, vegetables, and spices. A short 
list was prepared from promising plants that accumulate 
evidence-based (i.e. Cov-2 spike protein pseudotyped HT-
screened) BIOFLAVONOIDS (Table 3) that may fight with 
COVID infections. Since it is well known that the ACE2, the 
type2 pro-angiotensin cleaving enzyme is the key receptor of 
CoV-2 entry (Fig.3), thus, “to maintain and promote a normal 
blood pressure” (statement of EFSA) cocoa has been also 
incorporated as source of selective and bioactive 
FLAVONOLs (Table 2). 
 
Table 2. The most promising bioflavonoids, FLAVONES and 
FLAVONOLS selected, some of them have already tested in 
assays specific for Cov-2 spike protein pseudotyped virus 
displacement. 
Flavones Flavonols 
Apigenin Artemetin Myricetin Mearnsetin-
glucoside 
Luteolin Chrysos-
plenol C 
Gossypetin-3-
dimethyl ether 
Chrysos-
plenetin 
Luteolin-7-
methyl ether 
Chrysos-
plenol D 
Laricitrin 3,5-Dihydroxy-
3’,4’,6,7,tetra-
methoxyflavone 
Acacetin Mikanin Mearnsetin Syringetin 
Chrysoeriol Astragalin Quercetin Isokaempferide 
Chrysin Axillarin Quercetin-3-
methyl ether 
Quercetagetin 
3.4’-dimethyl-
ether 
Cirsinileol Casticin Quercimeritrin  
Cirsiliol Eupatin Retusin  
Cynaroside Kaempferol Rhamnetin  
Eupatorin Kaempferol-
6-methoxy-
glucoside 
Isorhamnetin  
Cirsimaritin Tamarixetin Rutin  
 
RESULTS  
 
The likelihood of recovering replication-competent virus also 
declines after onset of symptoms. For patients with mild to 
moderate COVID-19, replication-competent virus has not 
been recovered after 10 days following symptom onset (CDC, 
unpublished data, 2020; Wölfel et al., 2020; Arons et al., 
2020; Bullard et al., 2020; Lu et al., 2020; personal 
communication with Young et al., 2020; Korea CDC, 2020). 
Recovery of replication-competent virus between 10 and 20 
days after symptom onset has been documented in some 
persons with severe COVID-19 that, in some cases, was 
complicated by immunocompromised state (van Kampen et 
al., 2020). However, in this series of patients, it was estimated 
that 88% and 95% of their specimens no longer yielded 
replication-competent virus after 10 and 15 days, 
respectively, following symptom onset. 
 
A large contact tracing study demonstrated that high-risk 
household and hospital contacts did not develop infection if 
their exposure to a case patient started 6 days or more after 
the case patient’s illness onset (Cheng et al., 2020). 
 
Although replication-competent virus was not isolated 3 
weeks after symptom onset, recovered patients can continue 
to have SARS-CoV-2 RNA detected in their upper 
respiratory specimens for up to 12 weeks (Korea CDC, 2020; 
Li et al., 2020; Xiao et al, 2020). Investigation of 285 
“persistently positive” persons, which included 126 persons 
who had developed recurrent symptoms, found no secondary 
infections among 790 contacts attributable to contact with 
these case patients. Efforts to isolate replication-competent 
virus from 108 of these case patients were unsuccessful 
(Korea CDC, 2020). 
 
Specimens from patients who recovered from an initial 
COVID-19 illness and subsequently developed new 
symptoms and retested positive by RT-PCR did not have 
replication-competent virus detected (Korea CDC, 2020; Lu 
et al., 2020). The risk of reinfection may be lower in the first 
3 months after initial infection, based on limited evidence 
from another betacoronavirus (HCoV-OC43), the genus to 
which SARS-CoV-2 belongs (Kiyuka et al, 2018). 
 
Currently, almost a year after the emergence of SARS-CoV-
2, there have been several confirmed cases of SARS-CoV-2 
reinfection. However, the number of areas where sustained 
infection pressure has been maintained, and therefore 
reinfections would be most likely observed, remains limited. 
Serologic or other correlates of immunity have not yet been 
established. 
 
The current evidence includes the following caveats: 
In a recent study of skilled nursing facility workers followed 
prospectively for asymptomatic infection, one of 48 infected 
staff had a nasopharyngeal swab which was weakly positive 
on a single-passage plaque assay more than 20 days after 
initial diagnosis; however, the specimen was not subjected to 
serial passage to demonstrate the presence of replication-
competent virus (Quicke et al., 2020). 
 
In one case report, a person with mild illness provided 
specimens that yielded replication-competent virus for up to 
18 days after symptom onset (Liu et al., 2020). 
 
Data currently available are derived from adults; equivalent 
data from children and infants are not presently available. 
More data are needed concerning viral shedding in some 
situations, including in immunocompromised persons. 
 
Concentrations of SARS-CoV-2 RNA measured in upper 
respiratory specimens decline after onset of symptoms (CDC, 
unpublished data, 2020; Midgley et al., 2020; Young et al., 
2020; Zou et al., 2020; Wölfel et al., 2020; van Kampen et al., 
2020). 
 
Phytochemicals that prevent CoV-2 – ACE2 interactions 
Not only man made hexapeptides i.e. Tyr-Lys-Tyr- Arg-Tyr-
Leu, but either bioassay determined or clinically tried Anti-
CoV-2 selective flavonoid  inhibitors were uploaded in the 
AVIRA-DB, noted by text mining of the scientific and patent 
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literature since the 1st well documented coronavirus 
pandemics (Yi et al., 2004). From this repertoire beet 
(Sawicki et al., 2020), onion (Fuentes et al., 2020; Kwak et 
al., 2017), parsley leaves (Harrison, 2020), thyme, rosemary.  
(Jia et al., 2020; Li et al., 2020; Sun et al., 2020), oregano, 
cocoa (Balzer et al., 2006), safflower (J. Chen et al., 2020) 
were chosen with black pepper to promote absorption from 
the intestine to blood’s plasma. “BIOFLAVONOIDS also 
support a healthy immune system” (statement of EFSA) in 
fighting with any viral infection, since ACE2, the type2 pro-
angiotensin cleaving enzyme is the key receptor of CoV-2 
entry (Fig.3). “To maintain and promote a normal blood 
pressure” (statement of EFSA) cocoa has been incorporated 
as source of BIOFLAVONOLs in AVIRA. However, majority 
of pulverized plant ingredients, such as beet, onion of locally 
grown (Makó, Hungary Allium cepa var. cepa cv. Makói 
Bronz), parsley leaves, thyme, rosemary, oregano, and 
safflower are naturally enriched in POLYPHENOLIC and 
BIOFLAVONOID substances. 
 
Other phytochemicals have been determined with antiviral 
activities. Ivy tea was noted to improve acute bronchitis, one 
of the complications of Cov-2 infection  (Bester et al., 2020; 
Kruttschnitt et al., 2020). 
 
Repurposing  
From patentability point of view, either biotech or 
pharmaceutical companies, traditionally prefer repurposing 
prescription drug arsenal for new infective agents (Bester, 
Burger, & Maree, 2020; Kruttschnitt, Wegener, Zahner, & 
Henzen-Bucking, 2020).  The most advanced and so far the 
most successful drug repurposing clinical trial is going on 
with Remdesivir (RDV) which is a broad-spectrum adenosine 
triphosphate nucleoside anti-viral analog. It is an 
investigational small molecule developed by Gilad Sciences 
Inc. in 2015, primarily for the treatment of Ebola. RDV is in 
Phase–II trials to interevent Ebola virus-induced hemorrhagic 
fever (Hoenen, Groseth, & Feldmann, 2019). 
 
Another repurposing human clinical trial is being conducted 
with Favipiravir (FPV), a derivative of pyrazine 
carboxamide, is a promising broad-spectrum antiviral drug. 
FPV is initially developed for influenza, but also on H1N1, 
Ebola, Arena, and Bunya viruses. As far as the blocking 
mechanism is concerned FPV inhibits production of the 
mature retrovirus by preventing amplification of its genetic 
material by the viral-dependent polymerase.  It has been 
screened against many RNA viruses. Because of its action 
against RNA viruses, FPV approved, so far in Japan and 
France and not in other countries for a few indications 
(Khambholja & Asudani, 2020). To determine the viability of 
FPV for COVID-19 repurposing, we carried out a literature 
survey of clinical trials using FPV as an investigational drug 
for different indications. Results of the research published for 
a multi-centric Phase II study showed clinical effectiveness1 
 
1 https://clinicaltrials.gov/ct2/show/NCT01068912 
2 https://clinicaltrials.gov/ct2/show/NCT02026349  
of FPV in influenza in low-dose and high-dose treatment 
modalities with no mortality and no substantial possibility of 
severe adverse reactions2  
 
CoV-2 cross reactive vaccines from our childhood?  
There are also childhood vaccines that may be cross 
protective, due to the in silico testable cross-reactive 
antigenic motif-homology in their viral proteomes (i.e. spike, 
reverse transcriptase, polymerase etc.) (Fig.4). The recent 
isolates of highly contagious varieties of the SARS CoV-2, 
determined with significantly long homologous regions noted 
in spike proteins of Measles, Mumps and Rubella (MMR). 
Especially, the secondary structure alignment of the SARS-
CoV-2 Macro domain bound to ADP ribose as the template 
(Protein Data Bank entry 6W02) showed dramatic (SS)-
guided domain sequence homology with the rubella virus 
Macro domains (Fig.5). However, homology with spike 
protein of measles and mumps are quite obvious. 
Homologous protein domains in SARS-CoV-2 and measles, 
mumps and rubella viruses provide preliminary evidence that 
MMR vaccine might be protective against COVID-19 
therefore this immunization worth considering to stop the 
current SARS-CoV-2 pandemics (Sampaio, Rodrigues, 
Meireles, & Andrade Junior, 2020; Shanker, 2020).  
 
Infusion of anti-Cov-2 selective IgG-antibodies 
Recent anti-CoV-2 blood plasma transplantations of 
recovered CoV-2 (+) tested patients provided the proof-of-
principle of safety and efficacy of de novo produced anti-
CoV-2 specific IgG antibodies. However, one 0.5 liter plasma 
transplant rescue only one patient with severe complication 
that present considerable constraint of the treatment 
(Sheridan, 2020). Another potential problem is that 
antibodies in serum of convalescent patients following mild 
CoV-2 do not always prevent virus receptor binding, either 
due to the selectivity or efficay of the polyclonal IgG 
population (Gattinger et al., 2020).  
 
Structural analysis of human ACE2 recognition by 2019-
nCoV and SARS-CoVs  
All of these five residues of SARS CoVs, (see in Table 3) 
underwent natural selections and were shown to be critical for 
ACE2-recognition, cell entry, and host range of SARS-CoV 
RBM. The residue numbers are shown as in SARS CoV RBD, 
with the corresponding residue numbers in 2019-nCoV in 
parentheses (Wan et al., 2020).  
 
DISCUSSION 
 
Available data indicate that persons with mild to moderate 
COVID-19 remain infectious no longer than 10 days after 
symptom onset. Persons with more severe to critical illness 
or severe immunocompromise likely remain infectious no 
longer than 20 days after symptom onset.  Recovered persons 
can continue to shed detectable SARS-CoV-2 RNA in upper 
 
 © 2020 The Author(s). Ecocycles © European Ecocycles Society, ISSN 2416-2140                                                       Volume 6, Issue 2 (2020) 
 
43 
 
respiratory specimens for up to 3 months after illness onset, 
albeit at concentrations considerably lower than during 
illness, in ranges where replication-competent virus has not 
been reliably recovered and infectiousness is unlikely. The 
etiology of this persistently detectable SARS-CoV-2 RNA 
has yet to be determined. Studies have not found evidence 
that clinically recovered persons with persistence of viral 
RNA have transmitted SARS-CoV-2 to others. These 
findings strengthen the justification for relying on a symptom 
based, rather than test-based strategy for ending isolation of 
these patients, so that persons who are by current evidence no 
longer infectious are not kept unnecessarily isolated and 
excluded from work or other responsibilities. 
 
Table 3.  Critical residue changes in the RBMs of SARS-CoV 
and 2019-nCoV (Wan et al. 2020) 
 
Reinfection with SARS-CoV-2 has been definitively 
confirmed in recovered persons. If, and if so when, persons 
can be reinfected with SARS-CoV-2 remains unknown and is 
a subject of investigation. Persons infected with related 
endemic human betacoronavirus appear to become 
susceptible again at around 90 days after onset of  infection. 
Thus, for persons recovered from SARS-CoV-2 infection, a 
positive PCR during the 90 days after illness onset more 
likely represents persistent shedding of viral RNA than 
reinfection. If such a person remains asymptomatic during 
this 90-day period, then any re-testing is unlikely to yield 
useful information, even if the person had close contact with 
an infected person. 
 
If such a person becomes symptomatic during this 90-day 
period and an evaluation fails to identify a diagnosis other 
than SARS-CoV-2 infection (e.g., influenza), then the person 
may warrant evaluation for SARS-CoV-2 reinfection in 
consultation with an infectious disease or infection control 
expert. Isolation may be warranted during this evaluation, 
particularly if symptoms developed after close contact with 
an infected person. 
 
 
 
 
 
CONCLUSIONS 
Duration of isolation and precautions 
For most persons with COVID-19 illness, isolation and 
precautions can generally be discontinued 10 days after 
symptom onset1 and resolution of fever for at least 24 hours, 
without the use of fever-reducing medications, and with 
improvement of other symptoms. 
 
A limited number of persons with severe illness may produce 
replication-competent virus beyond 10 days that may warrant 
extending duration of isolation and precautions for up to 20 
days after symptom onset; consider consultation with 
infection control experts.  
 
For persons who never develop symptoms, isolation and other 
precautions can be discontinued 10 days after the date of their 
first positive RT-PCR test for SARS-CoV-2 RNA.  
 
For all others, a test-based strategy is no longer recommended 
except to discontinue isolation or precautions earlier than 
would occur under the strategy outlined in Part 1, above. 
 
Role of PCR testing2 after discontinuation of isolation or 
precautions 
For persons previously diagnosed with symptomatic COVID-
19 who remain asymptomatic after recovery, retesting is not 
recommended within 3 months after the date of symptom 
onset for the initial COVID-19 infection. 
 
For persons who develop new symptoms consistent with 
COVID-19 during the 3 months after the date of initial 
symptom onset, if an alternative etiology cannot be identified 
by a provider, then the person may warrant retesting; 
consultation with infectious disease or infection control 
experts is recommended. Isolation may be considered during 
this evaluation based on consultation with an infection 
control expert, especially in the event symptoms develop 
within 14 days after close contact with an infected person. For 
persons who never developed symptoms, the date of first 
positive RT-PCR test for SARS-CoV-2 RNA should be used 
in place of the date of symptom onset. 
 
Role of serologic testing 
Serologic testing should not be used to establish the presence 
or absence of SARS-CoV-2 infection or reinfection. 
Correlates of immunity to SARS-CoV-2 infection have not 
been established. Specifically, the utility of serologic testing 
to establish the absence or presence of infection or reinfection 
remains undefined. The recommendations are based on the 
best information available in mid-July 2020 and reflect the 
realities of an evolving pandemic. Even for pathogens for  
which many years of data are available, it may not be possible 
to establish recommendations that ensure 100% of persons 
who are shedding replication-competent virus remain 
isolated. CDC will continue to closely monitor the evolving 
science for information that would warrant reconsideration of 
these recommendations. 
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